Payment overview · 2025
General Payments
$2,914.24
77 reported records · 17 companies
Healthcare provider profile · identity verified
Steve Hou, M.D.,
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1245450204
Verified facts
What the public records show
CMS Open Payments records show Steve Hou, M.D., received $2,914.24 in general payments during 2025 across 77 reported records.
Gilead Sciences, Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Vemlidy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $626.88 | 21.5% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $428.75 | 14.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $320.34 | 11.0% | 10 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $285.29 | 9.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $263.51 | 9.0% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $223.57 | 7.7% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $191.15 | 6.6% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.00 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $121.10 | 4.2% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$98.16 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.12 | 2.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.24 | 1.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.98 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.14 | 0.7% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.67 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.61 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.73 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,914.24 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $285.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $263.75 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $223.57 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $208.55 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.55 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $121.10 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.10 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $109.19 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $98.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.24 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.50 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.87 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 57 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 174 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
57 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 707 | 186 |
| Vascepa | Icosapent Ethyl | 611 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 530 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 383 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 340 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 320 | 76 |
| Simvastatin | Simvastatin | 312 | 68 |
| Alendronate Sodium | Alendronate Sodium | 234 | 51 |
| Metformin Hcl | Metformin Hcl | 199 | 50 |
| Jardiance | Empagliflozin | 174 | 46 |
| Azithromycin | Azithromycin | 173 | 129 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 171 | 62 |
| Famotidine | Famotidine | 154 | 54 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 147 | 35 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 128 | 60 |
| Finasteride | Finasteride | 122 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 27 |
| Atenolol | Atenolol | 109 | 31 |
| Repaglinide | Repaglinide | 109 | 23 |
| Mirtazapine | Mirtazapine | 108 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 56 |
| Gabapentin | Gabapentin | 103 | 42 |
| Donepezil Hcl | Donepezil Hcl | 97 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 91 | 19 |
| Omeprazole | Omeprazole | 90 | 56 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 82 | 68 |
| Januvia | Sitagliptin Phosphate | 80 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 79 | 72 |
| Promethazine Hcl | Promethazine Hcl | 79 | 56 |
| Carvedilol | Carvedilol | 78 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 78 | 39 |
| Nateglinide | Nateglinide | 77 | 11 |
| Ammonium Lactate | Ammonium Lactate | 76 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 53 |
| Nifedipine Er | Nifedipine | 74 | 23 |
| Metformin Hcl Er | Metformin Hcl | 72 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 69 | 34 |
| Allopurinol | Allopurinol | 68 | 21 |
| Folic Acid | Folic Acid | 60 | 18 |
| Naproxen | Naproxen | 59 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 18 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 57 | 56 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 57 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 40 |
| Montelukast Sodium | Montelukast Sodium | 53 | 17 |
| Eliquis | Apixaban | 52 | 13 |
| Meclizine Hcl | Meclizine Hcl | 52 | 43 |
| Tradjenta | Linagliptin | 52 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 28 |
| Halobetasol Propionate | Halobetasol Propionate | 48 | 38 |
| Ketoconazole | Ketoconazole | 46 | 29 |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 31 |
| Loperamide | Loperamide Hcl | 42 | 34 |
| Propranolol Hcl | Propranolol Hcl | 42 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Lisinopril | Lisinopril | 39 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Acarbose | Acarbose | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 36 | suppressed |
| Furosemide | Furosemide | 35 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | 11 |
| Ozempic | Semaglutide | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | 29 |
| Diclofenac Epolamine | Diclofenac Epolamine | 32 | 17 |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 30 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Febuxostat | Febuxostat | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 28 | 20 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Mupirocin | Mupirocin | 26 | 18 |
| Trazodone Hcl | Trazodone Hcl | 26 | 19 |
| Kerendia | Finerenone | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 24 | 15 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 12 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | 12 |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Prolia | Denosumab | 18 | 15 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | 11 |
| Creon | Lipase/Protease/Amylase | 17 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Livalo | Pitavastatin Calcium | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | 11 |
| Meloxicam | Meloxicam | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,914.24 · 77 records | Gilead Sciences, Inc. | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, CLOSUREFAST, COLLAGENASE SANTYL, COMIRNATY, Cologuard Collection Kit, GARDASIL 9, JARDIANCE, KISUNLA, Kerendia, LINZESS, Leqembi, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, XIFAXAN, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error